EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis

Na-Yun Su iD, Qing Shi, Hao Mei, Jie Hu, Yu-Xiang Liu, Han-Ning Liu, Heng-Qi Liu, Yan Guo, Xing-Wei Wang, Chun-Hui Lan iD

Helicobacter · 2023

DOI: 10.1111/hel.13003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, 2023. Verfasst von Na-Yun Su und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Third Military Medical …. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

According to the Maastricht VI/Florence consensus report, potassium‐competitive acid blockers (P‐CAB) may improve Helicobacter pylori eradication treatment. Materials and methods A total of 213 H. pylori treatment‐naive patients aged between 18 and 70 years were treated with two regimens. The two regimens are VDT: 20 mg vonoprazan twice a day and 1 g amoxicillin three times daily and EDT: 20 mg esomeprazole four times a day and 750 mg amoxicillin four times daily. 13 C‐urea breath tests were used to evaluate eradication rate 4–6 weeks after treatment. Based on propensity score matching (PSM), this retrospective study analyzed the eradication rates, adverse events (AEs), compliance, and antibiotic resistance rates in VDT and EDT groups.

Results

On intention‐to‐treat (ITT) analysis, the eradication rate in VDT group (89.0%; 95% CI 81.7–96.3) was non‐inferior to that in EDT group (87.7%; 95% CI 80.1–95.3; p = 0.796). The corresponding per‐protocol (PP) eradication rates were 94.1% (95% CI 88.4–99.8) and 92.8% (95% CI 86.7–98.9; p = 1.000), respectively. There were no significant between‐group differences with respect to compliance or incidence of AEs.

Conclusions

The efficacy and safety of 14‐day VDT and EDT were comparable. Therefore, 14‐day VDT or EDT may be recommended for the first‐line treatment of H. pylori infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriHumansAdolescentYoung AdultAdultMiddle AgedAgedEsomeprazoleAnti-Bacterial AgentsRetrospective StudiesPropensity ScoreProton Pump InhibitorsAmoxicillinDrug Therapy, CombinationTreatment OutcomeClarithromycinPyrrolesSulfonamides

Stichwörter der Autor:innen

Helicobacter pylorieradication therapyhigh-dose dual therapyrisk factorsvonoprazan

Substanzen

EsomeprazoleAnti-Bacterial AgentsProton Pump InhibitorsAmoxicillinClarithromycin1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Third Military Medical University, Chongqing, China.

ORCID-Profile: Na-Yun Su, Chun-Hui Lan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission

Zitieren

APA

Su, N. Y., Shi, Q., Mei, H., Hu, J., Liu, Y. X., Liu, H. N., Liu, H. Q., Guo, Y., Wang, X. W., & Lan, C. H. (2023). Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter. https://doi.org/10.1111/hel.13003

Vancouver

Su NY, Shi Q, Mei H, Hu J, Liu YX, Liu HN, et al. Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter. 2023. doi:10.1111/hel.13003

BibTeX
@article{Su2023,
  author = {Su, Na-Yun and Shi, Qing and Mei, Hao and Hu, Jie and Liu, Yu-Xiang and Liu, Han-Ning and Liu, Heng-Qi and Guo, Yan and Wang, Xing-Wei and Lan, Chun-Hui},
  title = {Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis},
  journal = {Helicobacter},
  year = {2023},
  doi = {10.1111/hel.13003}
}
Kostenlos starten →